Tharimmune, Inc.-Naples Lunch 10/9/2024
Schedule
Wed Oct 09 2024 at 12:00 pm to 01:30 pm
UTC-04:00Location
Seasons 52 | Naples, FL
About this Event
*We anticipate 20 guests for this event. Due to limited seating, please make sure each individual registers accordingly. You will not be permitted to attend the event without proper registration.
Bear Creek Capital Presents:
Tharimmune, Inc. (NASDAQ: THAR)
Wednesday, October 9, 2024
Lunch
Season's 52
5630 Tamiami Trail
Naples, FL 34108
Promptly at 12:00 PM
Join Tharimmune, Inc. in this exclusive corporate presentation, followed by a Q & A session moderated by Bear Creek Capital, featuring questions taken from the audience.
We hope you can join our presentation
About Tharimmune, Inc.
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against specified targets.
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104
Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
Presentation Format:
12:00 p.m. to 1:30 p.m. – Presentation and Lunch
Contact:
Raymond Oliver
CEO, Bear Creek Capital
321-439-2120
Where is it happening?
Seasons 52, 8930 Tamiami Trail North, Naples, United StatesEvent Location & Nearby Stays:
USD 0.00
